Amon begins her talk by explaining what aneuploidy is and how it arises. She explains that autosomal aneuploidy is usually devastating to an organism, while aneuploidy at a cellular level may result in the unrestricted growth seen in cancer.
In Part 2, Amon provides more details about the impact of aneuploidy on individual cells. Using budding yeast and mouse lines engineered to have specific aneuploidies, Amon’s lab was able to show that aneuploid cells show gene specific effects, as well as a higher overall level of cellular stress.
Part 3 focuses on the role of aneuploidy in disease, specifically in cancer. Amon discusses how identifying enhancers and suppressors of the aneuploid condition can shed light on the effects of aneuploidy in cancer and can lead to the development of novel cancer therapeutics.
Angelika Amon received both her B.S. and Ph.D. degrees from the University of Vienna. She was a post-doctoral fellow at the Whitehead Institute and was subsequently named a Whitehead Fellow. In 1999, she joined the Massachusetts Institute of Technology where she is currently Professor of biology and Kathleen and Curtis Marble Professor in cancer research… Continue Reading